La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Merck Crescita futura

Future criteri di controllo 2/6

Merck prevede che gli utili e i ricavi cresceranno rispettivamente di 14.5% e 5.3% all'anno. Si prevede che l'EPS crescerà di 14% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 40.5% in 3 anni.

Informazioni chiave

14.5%

Tasso di crescita degli utili

14.0%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	23.6%
Tasso di crescita dei ricavi	5.3%
Rendimento futuro del capitale proprio	40.5%
Copertura analitica	Good
Ultimo aggiornamento	15 Aug 2024

Aggiornamenti recenti sulla crescita futura

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 01

Recent updates

Merck: Buy This Bargain Before It's Gone

Aug 12

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 01

Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins

Jul 31

Previsioni di crescita degli utili e dei ricavi

NYSE:MRK - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	72,668	25,603	26,221	29,717	22
12/31/2025	68,539	22,765	23,837	27,040	25
12/31/2024	64,164	18,856	18,780	23,946	24
6/30/2024	62,480	13,736	13,147	16,690	N/A
3/31/2024	61,403	2,306	11,040	14,757	N/A
12/31/2023	60,115	365	9,143	13,006	N/A
9/30/2023	59,314	4,608	13,167	17,190	N/A
6/30/2023	58,311	3,111	10,828	15,075	N/A
3/31/2023	57,869	13,030	11,262	15,673	N/A
12/31/2022	59,283	14,519	14,707	19,095	N/A
9/30/2022	58,974	15,322	15,249	19,696	N/A
6/30/2022	57,169	16,641	14,398	18,891	N/A
3/31/2022	53,978	13,910	12,870	17,220	N/A
12/31/2021	48,704	12,345	9,661	14,109	N/A
9/30/2021	46,131	5,908	8,401	13,072	N/A
6/30/2021	43,906	3,665	6,953	11,897	N/A
3/31/2021	41,857	4,793	6,659	11,184	N/A
12/31/2020	41,518	4,519	5,812	10,241	N/A
9/30/2020	42,438	9,492	6,906	11,041	N/A
6/30/2020	43,906	9,070	7,996	11,645	N/A
3/31/2020	46,312	9,399	8,947	12,811	N/A
12/31/2019	39,121	5,690	10,071	13,440	N/A
9/30/2019	45,970	9,314	8,973	12,238	N/A
6/30/2019	44,367	9,362	7,846	10,805	N/A
3/31/2019	43,073	8,399	8,343	11,103	N/A
12/31/2018	42,294	6,220	8,307	10,922	N/A
9/30/2018	41,729	3,347	8,948	11,349	N/A
6/30/2018	41,259	1,341	5,196	7,385	N/A
3/31/2018	40,725	1,579	N/A	7,320	N/A
12/31/2017	40,122	2,394	N/A	6,451	N/A
9/30/2017	39,804	2,845	N/A	6,064	N/A
6/30/2017	40,016	5,086	N/A	10,206	N/A
3/31/2017	39,929	4,346	N/A	8,489	N/A
12/31/2016	39,807	3,920	N/A	10,376	N/A
9/30/2016	39,907	5,492	N/A	10,990	N/A
6/30/2016	39,444	5,133	N/A	11,330	N/A
3/31/2016	39,385	4,614	N/A	12,427	N/A
12/31/2015	39,498	4,442	N/A	12,538	N/A
9/30/2015	39,765	10,781	N/A	7,128	N/A
6/30/2015	40,249	9,850	N/A	8,165	N/A
3/31/2015	41,398	11,168	N/A	7,783	N/A
12/31/2014	42,237	11,920	N/A	7,989	N/A
9/30/2014	43,075	5,385	N/A	12,050	N/A
6/30/2014	43,550	5,614	N/A	11,651	N/A
3/31/2014	43,626	4,516	N/A	11,674	N/A
12/31/2013	44,033	4,404	N/A	11,654	N/A
9/30/2013	44,450	4,531	N/A	10,437	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di MRK ( 14.5% all'anno) è superiore al tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Si prevede che gli utili di MRK ( 14.5% all'anno) cresceranno più lentamente rispetto al mercato US ( 15.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di MRK cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di MRK ( 5.3% all'anno) crescerà più lentamente rispetto al mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di MRK ( 5.3% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di MRK sarà molto alto tra 3 anni ( 40.5 %).

Merck Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Merck & Co., Inc. Revises Earnings Guidance for the Year 2024

Recent updates

Merck: Buy This Bargain Before It's Gone

Merck & Co., Inc. Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Merck & Co., Inc. Revises Earnings Guidance for the Year 2024

Insufficient new directors

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins

Merck Receives Positive Eu Chmp Opinion for Keytruda® (Pembrolizumab) PPlus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

First quarter dividend of US$0.77 announced

Merck Q2 Earnings Preview: We Need To Talk About Keytruda's LOE

Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Merck & Co., Inc. (NYSE:MRK) completed the acquisition of Eyebiotech Limited.

Merck: Positive Developments, But Watch The Q2 Earnings

Merck & Co., Inc.(NYSE:MRK) dropped from Russell 3000E Value Index

Merck: Among The Best Health Care GARP Plays Today

What Merck & Co., Inc.'s (NYSE:MRK) P/S Is Not Telling You

Merck Receives Positive EU CHMP Opinion for WINREVAIR (Sotatercept) in Pulmonary Arterial Hypertension (PAH)

CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults

Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer

Merck Announces FDA Approves Merck's Keytruda (Pembrolizumab) Plus Carboplatin and Paclitaxel as Treatment for Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma

Merck Announces U.S. FDA Approves Capvaxive (Pneumococcal 21-Valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults

Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

First quarter dividend of US$0.77 announced

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire Eyebiotech Limited for $3 billion.

Merck Declares Dividend for the Third Quarter of 2024, Payable on July 8, 2024

Merck Stock: Still Discounted To Graham P/E

Merck Announces Phase 3 KEYNOTE-522 Trial Met Its Overall Survival (OS) Endpoint in Patients with High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita